Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7079 USD | +3.33% | +7.26% | -85.57% |
Mar. 15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
Mar. 14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15.58M | Capitalization | 2.53M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.16 x |
P/E ratio 2024 * |
-0.32
x | P/E ratio 2025 * |
-0.55
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 26.26% |
Latest transcript on Quoin Pharmaceuticals, Ltd.
1 day | +3.33% | ||
1 week | +7.26% | ||
1 month | -25.48% | ||
3 months | -80.17% | ||
6 months | -82.61% | ||
Current year | -85.57% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Myers
CEO | Chief Executive Officer | 62 | 18-03-04 |
Denise Carter
FOU | Founder | 55 | 18-03-04 |
Gordon Dunn
DFI | Director of Finance/CFO | 60 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Sember
BRD | Director/Board Member | - | 21-10-27 |
Dennis Langer
BRD | Director/Board Member | 73 | 21-10-27 |
Joseph Cooper
BRD | Director/Board Member | 66 | 21-10-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 0.7079 | +3.33% | 33,213 |
24-04-29 | 0.6851 | +7.47% | 161,352 |
24-04-26 | 0.6375 | +1.19% | 56,890 |
24-04-25 | 0.63 | -0.33% | 242,254 |
24-04-24 | 0.6321 | -4.23% | 55,115 |
Delayed Quote Nasdaq, April 30, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.57% | 2.53M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- QNRX Stock